You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNiflumic Acid
Accession NumberDB04552  (EXPT02331)
TypeSmall Molecule
GroupsApproved
DescriptionAn analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. [PubChem]
Structure
Thumb
Synonyms
Acide niflumique
Acido niflumico
Acidum niflumicum
NFA
Niflugel
External Identifiers
  • Lopac-N-0630
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NiflamNot Available
NiflugelNot Available
NiflurilNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4U5MP5IUD8
CAS number4394-00-7
WeightAverage: 282.218
Monoisotopic: 282.061612157
Chemical FormulaC13H9F3N2O2
InChI KeyInChIKey=JZFPYUNJRRFVQU-UHFFFAOYSA-N
InChI
InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
IUPAC Name
2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid
SMILES
OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPyridinecarboxylic acids and derivatives
Direct ParentPyridinecarboxylic acids
Alternative Parents
Substituents
  • Pyridine carboxylic acid
  • Aminopyridine
  • Imidolactam
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Azacycle
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the treatment of rheumatoid arthritis.
PharmacodynamicsNiflumic acid, a nonsteroidal anti-inflammatory fenamate, is a Ca2+-activated Cl- channel blocker.
Mechanism of actionNiflumic acid is able to inhibit both phospholipase A2 as well as COX-2, thereby acting as an antiinflamatory and pain reduction agent.
Related Articles
AbsorptionWell absorbed following oral administration.
Volume of distributionNot Available
Protein binding90% bound to plasma proteins.
Metabolism

Hepatic.

Route of eliminationNot Available
Half life2.5 hours
ClearanceNot Available
ToxicityOral, mouse: LD50 = 350 mg/kg; Oral, rat: LD50 = 250 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9298
Blood Brain Barrier+0.9115
Caco-2 permeable+0.5318
P-glycoprotein substrateNon-substrate0.7803
P-glycoprotein inhibitor INon-inhibitor0.8783
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9236
CYP450 2C9 substrateNon-substrate0.7654
CYP450 2D6 substrateNon-substrate0.8881
CYP450 3A4 substrateNon-substrate0.776
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.7762
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7812
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8322
BiodegradationNot ready biodegradable0.992
Rat acute toxicity3.0838 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.988
hERG inhibition (predictor II)Non-inhibitor0.7993
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point203 °CNot Available
water solubility19 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.43TAKACS-NOVAK,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0883 mg/mLALOGPS
logP4.33ALOGPS
logP3.12ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)1.88ChemAxon
pKa (Strongest Basic)5.51ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.22 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity65.93 m3·mol-1ChemAxon
Polarizability24.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.79 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Criddle DN, de Moura RS, Greenwood IA, Large WA: Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. Br J Pharmacol. 1997 Mar;120(5):813-8. [PubMed:9138686 ]
External Links
ATC CodesM02AA17M01AX02
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (73.3 KB)
Interactions
Drug Interactions
Drug
AbciximabNiflumic Acid may increase the anticoagulant activities of Abciximab.
AcebutololNiflumic Acid may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Aceclofenac.
AcenocoumarolNiflumic Acid may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Niflumic Acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Niflumic Acid.
Alendronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alendronic acid.
AliskirenNiflumic Acid may decrease the antihypertensive activities of Aliskiren.
AlprenololNiflumic Acid may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Niflumic Acid.
AmikacinNiflumic Acid may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideNiflumic Acid may decrease the antihypertensive activities of Amiloride.
AncrodNiflumic Acid may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Niflumic Acid.
Antithrombin III humanNiflumic Acid may increase the anticoagulant activities of Antithrombin III human.
ApixabanNiflumic Acid may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Apremilast.
ArdeparinNiflumic Acid may increase the anticoagulant activities of Ardeparin.
ArgatrobanNiflumic Acid may increase the anticoagulant activities of Argatroban.
ArotinololNiflumic Acid may decrease the antihypertensive activities of Arotinolol.
AtenololNiflumic Acid may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Niflumic Acid.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Niflumic Acid.
BalsalazideNiflumic Acid may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Niflumic Acid.
BecaplerminNiflumic Acid may increase the anticoagulant activities of Becaplermin.
BefunololNiflumic Acid may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Niflumic Acid.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Niflumic Acid.
BenoxaprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Benoxaprofen.
BetaxololNiflumic Acid may decrease the antihypertensive activities of Betaxolol.
BevantololNiflumic Acid may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Niflumic Acid.
BisoprololNiflumic Acid may decrease the antihypertensive activities of Bisoprolol.
BivalirudinNiflumic Acid may increase the anticoagulant activities of Bivalirudin.
BopindololNiflumic Acid may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Niflumic Acid.
BufuralolNiflumic Acid may decrease the antihypertensive activities of Bufuralol.
BumetanideNiflumic Acid may decrease the diuretic activities of Bumetanide.
BupranololNiflumic Acid may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Niflumic Acid.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Niflumic Acid.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Niflumic Acid.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Niflumic Acid.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Niflumic Acid.
CarteololNiflumic Acid may decrease the antihypertensive activities of Carteolol.
CarvedilolNiflumic Acid may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Niflumic Acid.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Niflumic Acid.
CeliprololNiflumic Acid may decrease the antihypertensive activities of Celiprolol.
CertoparinNiflumic Acid may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Niflumic Acid.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Niflumic Acid.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Niflumic Acid.
CholestyramineCholestyramine can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Niflumic Acid.
Citric AcidNiflumic Acid may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Niflumic Acid.
ColesevelamColesevelam can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineNiflumic Acid may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with D-Limonene.
Dabigatran etexilateNiflumic Acid may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinNiflumic Acid may increase the anticoagulant activities of Dalteparin.
DanaparoidNiflumic Acid may increase the anticoagulant activities of Danaparoid.
DaunorubicinNiflumic Acid may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Deferasirox.
DesirudinNiflumic Acid may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Niflumic Acid.
DextranNiflumic Acid may increase the anticoagulant activities of Dextran.
Dextran 40Niflumic Acid may increase the anticoagulant activities of Dextran 40.
Dextran 70Niflumic Acid may increase the anticoagulant activities of Dextran 70.
Dextran 75Niflumic Acid may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Niflumic Acid.
DicoumarolNiflumic Acid may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Niflumic Acid.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Niflumic Acid.
DihydrostreptomycinNiflumic Acid may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Niflumic Acid.
DoxorubicinNiflumic Acid may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneNiflumic Acid may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Droxicam.
Edetic AcidNiflumic Acid may increase the anticoagulant activities of Edetic Acid.
EdoxabanNiflumic Acid may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Niflumic Acid.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Niflumic Acid.
EnoxaparinNiflumic Acid may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Epirizole.
EpirubicinNiflumic Acid may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneNiflumic Acid may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Niflumic Acid.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Niflumic Acid.
EsmololNiflumic Acid may decrease the antihypertensive activities of Esmolol.
Etacrynic acidNiflumic Acid may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Niflumic Acid.
Ethyl biscoumacetateNiflumic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Niflumic Acid.
EtofenamateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Niflumic Acid.
Evening primrose oilThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Niflumic Acid.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Niflumic Acid.
FlunixinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Niflumic Acid.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Niflumic Acid.
Fondaparinux sodiumNiflumic Acid may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Niflumic Acid.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Niflumic Acid.
FramycetinNiflumic Acid may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideNiflumic Acid may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Niflumic Acid.
GentamicinNiflumic Acid may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Haloperidol.
HeparinNiflumic Acid may increase the anticoagulant activities of Heparin.
HirulogNiflumic Acid may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Niflumic Acid is combined with HMPL-004.
HydralazineNiflumic Acid may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Niflumic Acid.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Niflumic Acid.
Hygromycin BNiflumic Acid may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Niflumic Acid.
IbuproxamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Icatibant.
IdarubicinNiflumic Acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Niflumic Acid.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Niflumic Acid.
IndenololNiflumic Acid may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Niflumic Acid.
IndoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Niflumic Acid.
IsoxicamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Isoxicam.
KanamycinNiflumic Acid may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Niflumic Acid.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Niflumic Acid.
LabetalolNiflumic Acid may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Niflumic Acid.
LepirudinNiflumic Acid may increase the anticoagulant activities of Lepirudin.
LevobunololNiflumic Acid may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Niflumic Acid.
LithiumThe serum concentration of Lithium can be increased when it is combined with Niflumic Acid.
LornoxicamThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Niflumic Acid.
LoxoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Niflumic Acid.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Niflumic Acid.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Niflumic Acid.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Niflumic Acid.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Niflumic Acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Niflumic Acid.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Niflumic Acid.
MesalazineNiflumic Acid may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Niflumic Acid.
MetamizoleThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Niflumic Acid.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Niflumic Acid.
MetipranololNiflumic Acid may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic Acid.
MetoprololNiflumic Acid may decrease the antihypertensive activities of Metoprolol.
MetrizamideNiflumic Acid may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Niflumic Acid.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Niflumic Acid.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Niflumic Acid.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Niflumic Acid.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Niflumic Acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Niflumic Acid.
NadololNiflumic Acid may decrease the antihypertensive activities of Nadolol.
NadroparinNiflumic Acid may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Niflumic Acid.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Niflumic Acid.
NCX 4016The risk or severity of adverse effects can be increased when Niflumic Acid is combined with NCX 4016.
NeomycinNiflumic Acid may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nepafenac.
NetilmicinNiflumic Acid may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NimesulideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Niflumic Acid.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Niflumic Acid.
OlsalazineNiflumic Acid may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Niflumic Acid.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Niflumic Acid.
OrgoteinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Orgotein.
OtamixabanNiflumic Acid may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Niflumic Acid.
OxprenololNiflumic Acid may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Niflumic Acid.
PamidronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Parecoxib.
ParomomycinNiflumic Acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololNiflumic Acid may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateNiflumic Acid may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Niflumic Acid.
PhenindioneNiflumic Acid may increase the anticoagulant activities of Phenindione.
PhenprocoumonNiflumic Acid may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Niflumic Acid.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Niflumic Acid.
PindololNiflumic Acid may decrease the antihypertensive activities of Pindolol.
PiretanideNiflumic Acid may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Niflumic Acid.
PlicamycinNiflumic Acid may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Niflumic Acid.
PractololNiflumic Acid may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Niflumic Acid.
ProbenecidThe serum concentration of Niflumic Acid can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Propacetamol.
PropranololNiflumic Acid may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Niflumic Acid.
Protein CNiflumic Acid may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeNiflumic Acid may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Niflumic Acid is combined with PTC299.
PuromycinNiflumic Acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Niflumic Acid.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Niflumic Acid.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Niflumic Acid.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Niflumic Acid.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Niflumic Acid.
ReviparinNiflumic Acid may increase the anticoagulant activities of Reviparin.
RibostamycinNiflumic Acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Risedronate.
RivaroxabanNiflumic Acid may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Niflumic Acid.
SalicylamideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Niflumic Acid.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Niflumic Acid.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Niflumic Acid.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Niflumic Acid.
SeratrodastThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Seratrodast.
SotalolNiflumic Acid may decrease the antihypertensive activities of Sotalol.
SpectinomycinNiflumic Acid may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Niflumic Acid.
SpironolactoneNiflumic Acid may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Niflumic Acid is combined with SRT501.
StreptomycinNiflumic Acid may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinNiflumic Acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineNiflumic Acid may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Niflumic Acid.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Niflumic Acid.
SulodexideNiflumic Acid may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Niflumic Acid.
TacrolimusNiflumic Acid may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Niflumic Acid.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Niflumic Acid.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Niflumic Acid.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Niflumic Acid.
TenofovirThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Niflumic Acid.
TepoxalinThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Niflumic Acid.
TiludronateThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tiludronate.
TimololNiflumic Acid may decrease the antihypertensive activities of Timolol.
TobramycinNiflumic Acid may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Niflumic Acid.
TorasemideNiflumic Acid may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Niflumic Acid.
TranilastThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Niflumic Acid.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Niflumic Acid.
TriamtereneNiflumic Acid may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Niflumic Acid.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Niflumic Acid.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Niflumic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Niflumic Acid.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Niflumic Acid.
WarfarinNiflumic Acid may increase the anticoagulant activities of Warfarin.
XimelagatranNiflumic Acid may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Niflumic Acid.
Zoledronic acidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.
Gene Name:
PLA2G1B
Uniprot ID:
P04054
Molecular Weight:
16359.535 Da
References
  1. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19. [PubMed:16301791 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19. [PubMed:16301791 ]
  2. Diao HL, Zhu H, Ma H, Tan HN, Cong J, Su RW, Yang ZM: Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42. [PubMed:17485303 ]
  3. Alpert E, Gruzman A, Tennenbaum T, Sasson S: Selective cyclooxygenase-2 inhibitors stimulate glucose transport in L6 myotubes in a protein kinase Cdelta-dependent manner. Biochem Pharmacol. 2007 Feb 1;73(3):368-77. Epub 2006 Oct 13. [PubMed:17098211 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Voltage-gated chloride channel activity
Specific Function:
Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms.
Gene Name:
CLCNKA
Uniprot ID:
P51800
Molecular Weight:
75284.08 Da
References
  1. Picollo A, Liantonio A, Babini E, Camerino DC, Pusch M: Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels. J Membr Biol. 2007 Apr;216(2-3):73-82. Epub 2007 Jul 21. [PubMed:17659402 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Talbot S, Lin JC, Lahjouji K, Roy JP, Senecal J, Morin A, Couture R: Cigarette smoke-induced kinin B1 receptor promotes NADPH oxidase activity in cultured human alveolar epithelial cells. Peptides. 2011 Jul;32(7):1447-56. doi: 10.1016/j.peptides.2011.05.005. Epub 2011 May 11. [PubMed:21600945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipase a2 activity
Specific Function:
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:
PLA2G4A
Uniprot ID:
P47712
Molecular Weight:
85238.2 Da
References
  1. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19. [PubMed:16301791 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6. [PubMed:16278927 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Functions as high-affinity pyruvate transporter.
Gene Name:
SLC16A7
Uniprot ID:
O60669
Molecular Weight:
52199.745 Da
References
  1. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW: Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35. [PubMed:10417314 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bod...
Gene Name:
SLC16A1
Uniprot ID:
P53985
Molecular Weight:
53943.685 Da
References
  1. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW: Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35. [PubMed:10417314 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:24